<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118415</url>
  </required_header>
  <id_info>
    <org_study_id>NSCLC-TKD/IL-2</org_study_id>
    <secondary_id>2008-002130-30</secondary_id>
    <nct_id>NCT02118415</nct_id>
  </id_info>
  <brief_title>Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)</brief_title>
  <official_title>Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients
      with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with non-small cell lung carcinoma (NSCLC) in stage III A and III B showing at least
      stable disease after RCTx will be enrolled into the clinical trial. The aim of the study is
      to show the efficacy of an adjuvant treatment with Hsp70-peptide TKD/IL-2 activated,
      autologous NK cells following completion of standard radiochemotherapy
      (Cisplatin/Vinorelbine). Patients will be randomized 1:1 either to the interventional study
      group to receive 4 cycles of autologous immunotherapy with activated NK cells or to the
      control group (BSC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>follow up after randomization for at least 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>follow up after randomization for at least 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity (AE and SAE)</measure>
    <time_frame>follow up after randomization for at least 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QoLQ-30, LC-13)</measure>
    <time_frame>follow up after randomization for at least 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological parameters (NK cell activation)</measure>
    <time_frame>follow up after randomization for at least 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>NSCLC Stage IIIA/B</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional group: activated autologous NK cell treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group: BSC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hsp70-peptide TKD/IL-2 activated, autologous NK cells</intervention_name>
    <description>Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First diagnosis of histologically and/or cytologically proven and unresectable NSCLC
             with clinically stage III A and III B

          -  Completion of radiochemotherapy no longer than 8 weeks ago

          -  Progression free according to RECIST criteria at the first assessment after completion
             of RCTx

          -  Confirmed presence of Hsp70 on patient´s tumors

          -  ECOG Status(Appendices) ≤ 2

        Exclusion Criteria:

          -  Any severe heart disease or any severe concomitant disease (ECOG stage &gt; 2)

          -  NSCLC patients (stage IIIA/B) eligible for initial surgery with a confirmed consent of
             an interdisciplinary tumorboard

          -  Patients that show ALK positivity or an activating mutation of the EGFR-TK domain

          -  Patients with locally advanced or metastatic non-small cell lung cancer other than
             predominantly squamous cell histology

          -  Receipt of immunosuppressive drugs including high dose systemic corticosteroids within
             3 weeks before study entry. Low dose corticosteroids as they are a common treatment
             option for patients suffering from COPD are not an exclusion criterium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanno Specht, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar, TU München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanno Specht, Dr.</last_name>
    <phone>+49(0)89 4140 6469</phone>
    <email>hanno.specht@mri.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriele Multhoff, Prof.</last_name>
    <phone>+49(0)89 4140 4514</phone>
    <email>gabriele.multhoff@mri.tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Strahlentherapie und Radiologische Onkologie</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanno Specht, Dr.</last_name>
      <phone>+49 (0)89 4140</phone>
      <phone_ext>5910</phone_ext>
      <email>Hanno.Specht@mri.tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>not eligible for surgery</keyword>
  <keyword>efficacy of immunotherapy following RCTx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

